Home › Funds › RA CAPITAL MANAGEMENT, L.P. › TSHA

RA CAPITAL MANAGEMENT, L.P. position in TSHA

TAYSHA GENE THERAPIES INC · Health Care

RA CAPITAL MANAGEMENT, L.P. reported holding 23,555,648 shares of TSHA (TAYSHA GENE THERAPIES INC) in its Q2 2026 13F filing — a position valued at US$160.4M, representing 1.39% of its reported portfolio and ranking #18 among its reported holdings. RA CAPITAL MANAGEMENT, L.P. has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)23.56M sh
Reported value held$160.41M
Portfolio Weight1.39%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How RA CAPITAL MANAGEMENT, L.P.'s TSHA position evolved

RA CAPITAL MANAGEMENT, L.P. first disclosed a stake in TSHA in Q3 2023 at 18,472,503 shares (US$58.4M). The position peaked in Q2 2026 at 23,555,648 shares, worth US$160.4M. Across 12 filings, RA CAPITAL MANAGEMENT, L.P. increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 9 time(s). The most recent filing (Q2 2026) shows 23,555,648 shares valued at US$160.4M. Notable position changes include a 41% trim in Q1 2024 (shares fell 22% over the following quarter), a 117% increase in Q2 2025 (shares rose 42% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 18.47M $58.37M New
Q4 2023 18.47M $32.70M Hold
Q1 2024 10.87M $31.20M Reduce
Q2 2024 10.87M $24.35M Hold
Q3 2024 10.87M $21.85M Hold
Q4 2024 10.87M $18.81M Hold
Q1 2025 10.87M $15.11M Hold
Q2 2025 23.56M $54.41M Add
Q3 2025 23.56M $77.03M Hold
Q4 2025 23.56M $129.56M Hold
Q1 2026 23.56M $105.29M Hold
Q2 2026 23.56M $160.41M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TSHA and 13F data

TSHA (TAYSHA GENE THERAPIES INC) is a Health Care company. 56 other funds we track also report a position in TSHA — the largest reported positions include Avoro Capital Advisors LLC (US$162.7M), Vestal Point Capital, LP (US$132.2M), RTW INVESTMENTS, LP (US$92.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TSHA

All TSHA fund holders →

FAQ

How long has RA CAPITAL MANAGEMENT, L.P. held TSHA?

RA CAPITAL MANAGEMENT, L.P. has disclosed TSHA holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is RA CAPITAL MANAGEMENT, L.P.'s current position in TSHA?

As of Q2 2026, RA CAPITAL MANAGEMENT, L.P. holds 23.56M shares of TSHA (TAYSHA GENE THERAPIES INC), valued at $160.41M, representing 1.39% of its reported portfolio and ranking #18.

Has RA CAPITAL MANAGEMENT, L.P. been buying or selling TSHA?

In the latest 13F filing (Q2 2026), RA CAPITAL MANAGEMENT, L.P. held unchanged its position in TSHA. The position peaked in Q2 2026 at 23.56M shares.

Which other funds hold TSHA?

Other major institutional holders of TSHA include Avoro Capital Advisors LLC, Vestal Point Capital, LP, RTW INVESTMENTS, LP, among 56 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.